Showing 1894 results
August 2016
-
Press release
Novartis announces positive phase III results showing efficacy of BAF312 in patients with secondary progressive MS
The Phase III EXPAND study of BAF312 (siponimod) in secondary progressive multiple sclerosis (SPMS) met its primary endpoint of reducing the risk of three-month confirmed disability progression… -
Featured News
Taking action for psoriasis patients: the WHO psoriasis resolution
The World Health Organization (WHO) passed a resolution on psoriasis that creates an urgent call to action for the international community.
-
In The News
Reigniting a passion for science
How two years in a Novartis lab changed Johnny Castillo's life -
Story Discovery
Stifling danger signals in rheumatoid arthritis
Blocking an inflammatory pathway may offer a new way to treat autoimmune disease.
-
Press release
Six leading scientists to receive prestigious Novartis Prizes for Immunology at 16th International Congress of Immunology
The Basic Immunology Prize is awarded to John Kappler, Philippa Marrack and Harald von Boehmer for demonstrating that the ability of the immune system to discriminate "self" from "non-self" is… -
Story Access to Healthcare
Kenya confronts chronic diseases, building on progress against AIDS
While the country has made great strides in controlling AIDS and other infectious diseases, Kenyans are living longer and chronic diseases such as diabetes, heart disease and cancer are on the rise.
-
Press release
Novartis CDK4/6 inhibitor LEE011 (ribociclib) receives FDA Breakthrough Therapy designation as first-line treatment for HR+/HER2- advanced breast cancer
Designation underscores the continuing unmet need of the HR+/HER2- advanced breast cancer population and the potential of LEE011 (ribociclib) as an effective new treatment option Results… -
Press release
Alcon achieves US approval for CyPass® Micro-Stent, a micro invasive surgical device to treat glaucoma
US Food and Drug Administration (FDA) grants approval for CyPass Micro-Stent for sale in the US, expanding Alcon's surgical presence to treat glaucoma The CyPass Micro-Stent is designed to…
July 2016
-
In The News
Novartis Access perspectives: How new business models can help fight chronic diseases
An editorial by Harald Nusser, Head Novartis Access & Malaria Initiative, in DEVEX -
Story From Our Labs
Reigniting a passion for science
How two years in a Novartis lab changed Johnny Castillo’s life.
-
Press release
Novartis delivered solid Q2 despite full quarter of US Gleevec generic impact; significant positive innovation news strengthens future growth prospects
Q2 net sales were flat (0% cc[1]) as Growth Products[2] offset Gleevec generic impact Gilenya (USD 811 million, +17% cc) continued to grow double-digit mainly due to volume growth Cosentyx (… -
Press release
Novartis réalise un 2ème trimestre solide, malgré l'impact sur le trimestre du générique de Gleevec aux US; nouvelles positives importantes de l'innovation renforcent les perspectives de croissance
Chiffre d'affaires net du T2 stable (0% tcc[1]), les produits de croissance[2] ayant compensé l'impact du générique de Gleevec Gilenya (USD 811 millions, +17% tcc) a continué de croître à un taux…